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Friedreich’s ataxia is the most common inherited autosomal recessive ataxia and is characterized by progressive degeneration of the
peripheral and central nervous systems and cardiomyopathy. This disease is caused by the silencing of the FXN gene and reduced
levels of the encoded protein, frataxin. Frataxin is a mitochondrial protein that functions primarily in iron-sulfur cluster synthesis.
This small protein with an 𝛼/𝛽 sandwich fold undergoes complex processing and imports into the mitochondria, generating
isoforms with distinct N-terminal lengths whichmay underlie different functionalities, also in respect to oligomerization.Missense
mutations in the FXN coding region, which compromise protein folding, stability, and function, are found in 4% of FRDA
heterozygous patients and are useful to understand how loss of functional frataxin impacts on FRDA physiopathology. In cells,
frataxin deficiency leads to pleiotropic phenotypes, including deregulation of iron homeostasis and increased oxidative stress.
Increasing amount of data suggest that oxidative stress contributes to neurodegeneration in Friedreich’s ataxia.
1. Friedreich’s Ataxia: Origin, Clinical
Features, and Neurodegeneration
The main feature of Friedreich’s ataxia (FRDA) disease is
progressive and unremitting ataxia [1–3]. The first symp-
toms appear at puberty but onset of the disease can occur
from infancy to after 60 years [4]. Major neurologic signs
include gait and limb ataxia, tendon areflexia, dysarthria,
sensory loss, and pyramidal signs [5]. Cardiomyopathy is a
frequent symptom and is associated with a severe prognosis,
particularly in young patients [6]. Some patients can also
develop skeletal deformation, ocular abnormalities, hearing
loss, and diabetes [5]. The neuropathology of FRDA involves
degeneration of the dorsal root ganglia, peripheral nerves,
the spinal cord, and the dentate nucleus in the cerebellum
[7]. Patient nerves show axonal neuropathy with loss of large
myelinated fibers and an increase in the number of small
unmyelinated fibers [8, 9].
FRDA is caused by a GAA trinucleotide repeat expansion
in the first intron of the FXN gene [10]. The majority of
patients are homozygous for the trinucleotide expansion but
in 4% of patients, one allele presents point mutations in the
coding region. Expanded alleles lead to the inhibition of
FXN expression resulting in decreased levels of the encoded
protein, frataxin [10, 11].The transcriptional repression of the
FXN gene induced by the GAA expansion is due to arrest
of RNA polymerase II progression and to heterochromatin-
mediated gene silencing [12–16]. Frataxin is a mitochondrial
protein involved in cellular iron use and maintenance of the
redox status [4]. Although the function of frataxin has been
a matter of debate since its discovery, it is now generally
accepted that its primary function is in iron-sulfur cluster
biosynthesis [17–20].
Frataxin is expressed in all cells of eukaryotic organisms.
However, the levels of FXN mRNA and frataxin show tissue
specificity that partially correlates with the sites of disease.
In humans, the highest levels of expression are found in
the heart and spinal cord and lower levels are observed in
the cerebellum, liver, skeletal muscle, and pancreas [10]. The
differential sensitivity of the tissues to frataxin deficiency is
not clear but may depend on the cellular metabolism and/or
on the somatic instability of expanded GAA triplet repeats
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Figure 1: Structures of the frataxinmonomer and trimer, denoting the typical 𝛼/𝛽 fold in which the 𝛼-helices pack against the𝛽-sheet strands.
(a) Structure of the human frataxin monomer (PDB: 3S4M). (b) Structure of the yeast frataxin trimer (PDB: 3OEQ). Note that in the trimer
structure, unwinding of the N-terminal 𝛼-helix affords an interaction with a 𝛽-sheet from the nearby subunit.
[4, 21]. For dorsal root ganglia, one of the first tissues affected
in FRDA patients, it was shown that somatic instability starts
during embryonic development and continues throughout
life, resulting in progressive, age-dependent accumulation of
larger GAA triplet repeat expansions [21, 22]. Nevertheless,
understanding why only certain tissues are sensitive to
frataxin depletionwill contribute to a better understanding of
the pathophysiology of the disease. Oxidative stress has been
suggested to be one of the major inducers of neurodegenera-
tion, but the underlyingmechanisms are not fully understood
[4, 23, 24]. Antioxidant therapy has been tested since the
discovery of the gene with different molecules with limited
success in stopping the progression of the disease; however,
it is a potential target to treat the disease, and new molecules
are being tested.
2. The Frataxin Protein:
Structure and Function
Human frataxin (FXN) is a small protein, which is involved
in themitochondrial biogenesis of iron-sulfur clusters (ISCs).
These inorganic structures are essential redox cofactors found
in several respiratory and metabolic enzymes within mito-
chondria. Although frataxin function remains to be fully
elucidated at themolecular level, a wealth of biochemical data
and the determination of three-dimensional structures from
several homologues of FXN, particularly yeast frataxin (Yfh1),
have contributed to substantial progress on understanding
frataxin function [25–29].
The frataxin fold is characterized by a planar 𝛼-𝛽 sand-
wich motif, comprising two terminal 𝛼-helices, alongside
with five antiparallel 𝛽-strands that make up two planes
which are intersected by additional 𝛽-strands, thus compos-
ing the structure (Figure 1(a)). Several frataxins have been
shown to undergo oligomerization reactions, assembling
into trimers, hexamers, and larger order 24- and 48-mer
assemblies, although there is no consensus in the community
regarding the possibility of these reactions taking place in
vivo or on their functional relevance (Figure 1(b)). Frataxin
function involves participating in largermolecular assemblies
with the several components from the mitochondrial ISC
assembly machinery, and the molecular details of these
interactions are only now starting to be elucidated with
the disclosure of possible interactions taking place in such
quaternary complexes [30–32]. Nevertheless, other still con-
troversial roles have been proposed for frataxin, including
delivery of iron to ferrochelatase for heme synthesis, recovery
of the oxidatively damaged [3Fe4S] cluster in aconitase, and
iron storage (reviewed in [17]).
One important region in the frataxin fold is the so-
called acidic region, which comprises a set of acidic residues
located within the first 𝛼-helix and the edge of the first
𝛽-strand (𝛼1 and 𝛽1 in Figure 1(a)), that are involved in
low affinity iron-binding [33]. Nevertheless, iron-binding is
essential for the interaction between Yfh1 frataxin and the Isu
scaffold protein from the ISCmachinery [34]. Studies on Yfh1
focusing on a set of functional mutants in the acidic region
have shown that charge-to-neutral alterations in the ridge do
not abolish iron-binding, but rather decrease binding affinity
[35]. Indeed, frataxin iron-binding capacity is quite robust,
as even upon changing five of the most conserved residues
from the putative iron-binding region, at least two iron atoms
per monomer can be bound. This study has also elicited an
interesting trade-off between frataxin function and stability
of the fold. Although these negative charges have a functional
role, at the same time, they significantly impair Yfh1 stability
as their replacement results in a dramatic increase of protein
stability while reducing conformational plasticity. The acidic
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Figure 2: Mapping of amino acids mutated in FRDA compound heterozygous patients. FRDA mutations indicated on the human frataxin
structure (PDB: 3S4M): Lys106Ser, Asp122Tyr, Gly130Val, Asn146Lys, Gln148Arg, Ile154Phe, Trp155Arg, Leu156Pro, Arg165Cys, Trp173Gly,
Leu182Phe, Leu182His, and His183Arg. The arrow denotes a 90∘ rotation.
ridge has thus evolved to favor function over stability, there-
fore highlighting its importance on frataxin structure. On the
other hand, mutations of conserved residues of the portion
of the acid ridge found in the 𝛽-sheet, affected interaction
with the scaffold protein Isu, but did not affect overall protein
stability [35].
Frataxin processing and cleavage upon import into the
mitochondria results, in some cases, in the production of
diverse isoforms with distinct structural properties, espe-
cially in what concerns oligomerization propensity [36–38].
Human frataxin is a 210-amino acid protein which upon
expression in the cytosol is imported into the mitochondria
matrix, where it undergoes a complex processing resulting in
isoforms with different lengths at the N-terminus [36–38].
Identified isoforms include shorter frataxin versions (pro-
cessed at positions 42- and 56-) and longer ones (processed
at positions 78- and 81-). In humans, the most abundant
products seem to be themonomeric form FXN(81-201) which
predominates in fibroblasts, alongside with the oligomeriza-
tion prone longer FXN(42-120) isoform, which is abundant
in the heart, cerebellum, and dividing fibroblasts [39]. In fact,
distinct N-terminal processing of human frataxin has been
suggested to result in proteins with distinct functionalities in
what concerns interactions with the ISC machinery proteins
and iron-binding properties [17, 39]. In yeast, one major
form of processed frataxin is detected in the mitochondria
(corresponding to Yfh1 52-174), which seems to be present
mostly in the form of trimers, unless protein overexpression
takes place which then generates larger oligomers [40]. Stress
and increased iron uptake seem also to induce the formation
of higher order Yfh1 oligomers [41].
One aspect which remains to be fully investigated is
whether frataxin may be itself a target for oxidative modifi-
cations in the context of FRDA in which very low frataxin
levels are present with iron accumulation in an environment
prone to oxidative reactions. To establish a proof of principle,
the susceptibility of frataxin to amino acid carbonylation
and nitration was investigated [42]. The results on FXN(91-
210) showed that residues in the 𝛽-sheet surface (Tyr143,
Tyr174, Tyr205, and Trp155) were preferential targets, and
that modifications did not alter substantially iron binding or
protein stability. Interestingly, the strictly conserved Trp155,
which is mutated in early onset patients, is a hot spot for
modifications leading to the speculation that this could be
an effectivemechanism tomodulate frataxin interactions and
thus its function [42].
3. FRDA-Related Frataxin Mutations Result in
a Loss of Function Misfolding Disease
A small fraction of FRDA patients (around 4%) are com-
pound heterozygotes for the intronic GAA trinucleotide
repeat expansion, carrying in the other allele a missense
mutation in the coding region of the FXN gene (Figure 2).
These mutations are useful to understand how loss of
functional frataxin impacts on FRDA physiopathology. Some
of these mutations can be grouped according to FRDA symp-
toms severity: for example, whereas the FXN-p.Ile154Phe and
FXN-p.Trp155Arg mutations lead to severe FRDA, the muta-
tions FXN-p.Gly130Val and the FXN-p.Asp122Tyr account
for milder clinical symptoms, although the latter has a very
low prevalence [43]. Overall, the link between a point muta-
tion in frataxin and the disease physiopathology remains
unclear. Whereas first approaches shed light onto possible
molecular mechanisms of disease by analyzing effects of
mutations on protein folding and stability [44, 45], more
recently mutations have also been studied in the context of
cell models [46] and distinct frataxin isoforms with different
N-terminal processing [47], and for some mutants, crystal
structure information has been obtained [48].
The initial studies on FRDA frataxin mutants focused
on the aggressive phenotype FXN-p.Ile154Phe and FXN-
p.Trp155Arg variants, studied in the background of the
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shorter processed FXN(91-210) protein [44]. The former is
among the most common clinical mutation, and affects an
isoleucine residue at the protein core, and thus is expected
to directly affect the structure and stability of the protein
fold. The latter affects a conserved tryptophan residue at
the protein surface in the exposed region of a 𝛽-sheet. The
study has shown that these FRDA frataxin variants retained
the native fold under physiological conditions but were
thermodynamically destabilized in respect to normal frataxin
had a higher tendency towards proteolytic degradation, and
iron-binding was only partly impaired, nevertheless with
concomitant protein aggregation [44]. The implication of
these findings was that the severe mutations did not abolish
the expression of the FRDA frataxin variants, suggesting that
these proteins are formed under physiological conditions.
Interestingly, a FRDA murine fibroblast cell model based on
the FXN-p.Ile154Phe has corroborated this observation in
vivo, as transgenic expression of this pathological mutation
partly rescued endogenous frataxin deficiency [46]. Further,
these studies also evidenced decreased activity of iron-sulfur
proteins and accumulation of iron [46], in agreementwith the
poorer iron-binding ability which had been observed in vitro
[44].
The evidence that the pathogenic mechanism in FRDA
mutant frataxin results from frataxin misfolding and insta-
bility suggests that, although quite different from other
neurodegenerative diseases involving toxic aggregation and
metal ions [49], FRDA in compound heterozygous patients
can be classified as a protein misfolding disease [50]. In
order to further explore this possibility, a broader study
encompassing also frataxin mutations yielding the milder
FRDA forms FXN-p.Asp122Tyr and FXN-p.Gly130Val was
undertaken [45]. The conclusion from those studies showed
that FRDA frataxins exhibit distinct degrees of conforma-
tional defects that impair folding and function. For example,
protein degradation propensity does not correlate necessarily
with disease severity, as the twomilder mutations were found
for example to undergo proteolysis at higher rates than the
severe ones, which rather seem to expose more particular
part of the protein. An exploration of folding defects caused
by mutations resulting in a change in the soluble : insoluble
ratio upon recombinant expression showed that the severe
FXN-p.Trp155Arg and FXN-p.Ile154Phe variants are mostly
expressed as insoluble peptides, indicating that these muta-
tions affect early folding [45]. Interestingly these results
were corroborated by an investigation of the effects of these
mutations in the context of the isoforms FXN(42-210) and
FXN(81-210) in cell-free and different cellular models [47].
In addition, this study has shown that the FXN-p.Trp155Arg
mutation destabilizes FXN(42-210) to a greater extent, as the
mutation in this form makes the protein more susceptible to
in vivo degradation than in the FXN(81-210) form. Likewise,
the FXN-p.Ile154Phe variant in FXN(42-210) has a strongly
compromised solubility; however, in FXN(81-210) yields a
folded polypeptide when expressed in different cells types
[47], in agreement with the results obtained in vitro for the
purified recombinant mutant variant [45].
4. Oxidative Stress in Frataxin-Deficient Cells
and Neurodegeneration
Oxidative stress is a central feature of FRDAdisease and still a
privileged target for therapy [4, 23, 24]. An increasing amount
of data from different organisms support the hypothesis that
frataxin-deficiency causes a deregulation in the antioxidant
defenses, which result in oxidative stress and pathology [4,
24, 51, 52]. Increased levels of prooxidant molecules such as
H
2
O
2
and superoxide have been detected in yeast,Drosophila
and FRDA patient cells [40, 53–58]. In addition, frataxin
deficiency increases the cellular sensitivity to a wide variety
of prooxidants in yeast [58, 59], Caenorhabditis elegans [60],
Drosophila [56, 61, 62], mouse [63], and patient FRDA cells
[64–68].
The eukaryotic cellular response to oxidative stress
involves the induction of detoxifying enzymes such as super-
oxide dismutases (SODs), an increase in glutathione and
NADPH synthesis, a decrease in the reduced to oxidized
glutathione ratio and glutathionylation of target proteins [69].
SODs convert superoxide into H
2
O
2
and are upregulated
upon oxidant insult. However, in fibroblasts from FRDA
patients, unlike those from healthy controls, SODs are not
upregulated in response to low doses of H
2
O
2
, oligomycin,
and iron [57, 65, 66]. In yeast, the anaerobiosis to aerobiosis
transition is an inducer of oxidative stress in Δyfh1 cells
as a result of transcriptional repression of several genes
encoding critical antioxidant enzymes (SODs, catalases,
glutaredoxins, and thioredoxins) and of decrease of total
glutathione levels [58, 70]. Glutathione is a major antioxidant
molecule in eukaryotic cells. Furthermore, reversible protein
S-glutathionylation is a post translational modification that
provides protection of protein cysteines from irreversible
oxidation and also functions in the transduction of redox
signals [71]. Several studies show that frataxin deficiency
leads to the impairment of glutathione homeostasis [52,
53, 72–75]. A significant increase in the glutathione pool
bound to proteins was observed in blood samples, fibroblasts,
and lymphoblasts from FRDA patients and yeast Δyfh1
cells [72, 74, 75]. In addition, Pastore et al. found that in
patient fibroblasts actin was glutathionylated, which caused
disassembly of the filaments [74]. The analysis of autopsy
samples from the spinal cord of FRDA patients also showed
abnormal microfilament polymerization [76].
The discovery of actin glutathionylation and the demon-
stration that the Nrf2-dependent Phase II antioxidant path-
way is defective in patient fibroblasts provided the first
mechanism for the reduction of antioxidant defenses in
human frataxin-deficient cells [57]. Nuclear factor erythroid
2-related factor 2 (Nrf2) is a key transcription factor that
responds to oxidants by inducing expression of antioxidant
enzymes to restore redox homeostasis in the cell. The Nrf2
activity is regulated by the actin-associated Keap1 (Kelch-like
ECH-associated protein 1), which is an adaptor protein for the
Cul3-dependent E3 ubiquitin ligase complex. Under normal
conditions, Keap1 sequesters Nrf2 in the cytoplasm and
promotes its rapid degradation via ubiquitination [77]. Under
oxidative stress conditions, the cysteines of the Keap1 protein
became oxidized, and the activity of the Cul3-Keap1 ubiquitin
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E3 ligase complex is reduced. As a consequence, Nrf2 is
stabilized and translocated to the nucleus where it binds
to DNA sequences of the cis-acting antioxidant responsive
element (ARE), activating the expression of genes encoding
antioxidant enzymes like SODs, catalase, glutathione S-
transferase, and NADH quinone oxidoreductase [77]. In
fibroblasts from FRDA patients, Keap1 is not associated with
actin, and Nrf2 is distributed diffusely in the cell [57]. In
addition, in FRDAfibroblasts treatedwith oligomycin or tert-
butylhydroquinone, Nrf2 fails to translocate to the nucleus
and the antioxidant Phase II genes are not induced [57]. This
phenotype can be reversed by 24 h treatment with the catalase
mimetic Euk134; the actin stress fibers were reorganized, and
Nrf2-signalling was restored, highlighting the role of H
2
O
2
in FRDA pathophysiology. Recently, it was shown that the
PIP5K1B gene that is located upstream of the FXN gene is
also silenced in FRDA patient lymphocytes and fibroblasts
[48]. The pip5k1𝛽 protein is a key regulatory factor of actin
cytoskeleton dynamics, and its down-regulation in fibroblasts
causes actin network destabilization [48].Therefore, it is very
likely that in FRDA patient cells, PIP5K1B gene silencing
contributes to actin disassembly, but a direct evidence of
actin glutathionylation in cells deficient for pip5k1𝛽 protein
is missing.
Microarray analysis of dorsal root ganglia from YG8R
frataxin-deficient mice and controls revealed significant dif-
ferences in genes belonging to the thiol antioxidant, the
myelination, and the axon transport functional categories
[52]. In addition, the authors found not only a decreased
expression of antioxidant genes that are regulated byNrf2, but
also Nrf2 (at mRNA and protein levels) in YG8R dorsal root
ganglia compared to controls. However, their observations
using different cell lines (HeLa, fibroblast, andND7/23 dorsal
root ganglion neuron cell lines and patient lymphoblasts) did
not support deficient translocation of Nrf2 to the nucleus
upon oxidant insult; Nrf2 is being mainly localized in the
nucleus in frataxin-deficient cells. Consistent with these
data, D’Oria et al. found no increase in Nrf2 expression in
frataxin-silenced NSC34 cells (derived from the fusion of
neuroblastoma cells and spinal cord motor neurons) com-
pared to controls upon treatment with oxidized glutathione
neither an increase in the Nrf2 nuclear fraction [78]. Neurons
and fibroblasts are completely different cells types, and it
is possible that in neurons antioxidant defense regulation
depends primarily on Nrf2 levels while in fibroblasts it is the
actin-driven translocation to the nucleus the major regulator.
Chronic inflammation and activity of glial cells are
important factors that lead to neurodegeneration in other
diseases, such as Alzheimer’s disease and amyotrophic lateral
sclerosis [79]. In FRDA, degeneration affects different types of
neurons in the peripheral and central nervous systems, and
it is likely that other cell types are also affected by frataxin
deficiency. Several reports suggest that Schwann cells (SCs)
could be specifically affected and that peripheral neuron loss
would be a secondary event [9, 80]. Schwann cells are glial
cells specialized in the myelination of axons in the peripheral
nervous system. Signaling between neurons and SC plays
an essential role in SC proliferation, survival, migration,
and myelination [81]. On the opposite, SC also contributes
to the preservation of axon integrity [82]. Analysis of the
dorsal roots in patient autopsy samples shows differences in
the myelination of thin fibers and reduced number of SC
[9]. In addition, patient sural nerve autopsies also suggest
participation of SC in neurodegeneration since although the
large myelinated fibers are significantly reduced the total
number of axons per unit area is similar to that of controls
[83]. In agreement with these observations, in vitro studies
using human SC lines showed frataxin knock-downby siRNA
blocks cell cycle progression at G
2
M, and this is followed
by an inflammatory response and an increase in cell death
[80]. Treatment of these cells with antiinflammatory and
antiapoptotic drugs rescued the death phenotype. Altogether,
these results suggest that defects in SC could be at the origin
of hypomyelination or demyelination and axon degeneration
in FRDA patients.
5. Mitochondrial and Nuclear DNA Damage
Oxidative DNA damage is a natural consequence of aerobic
metabolism that is exacerbated when cells are in oxidative
stress conditions. ROS induce more than 20 lesions in the
DNA, such as oxidized bases, apurinic/apyrimidinic (AP)
sites, base deamination products, oxidized sugar fragments,
and DNA strand breaks [84]. Damaged DNA bases, if not
repaired, may have miscoding properties leading to mutation
upon replication or by blocking progression of the replication
fork [85, 86]. The most studied DNA lesion is the 8-
oxo-7,8-dihydro-2󸀠-deoxyguanosine (8-oxodG), a product of
oxidation of guanine. Conflicting results have been obtained
for the levels of urinary 8-oxodG between FRDA patients and
controls, since a difference has not always been found [87, 88].
However,mitochondrial and nuclearDNAdamage have been
reported in human, mouse, and yeast frataxin-deficient cells
[51, 89–92].
Mitochondrial DNA (mtDNA) loss was one of the first
phenotypes reported for the Δyfh1 yeast cells [93–95] and for
FRDApatient cells [96]. Karthikeyan et al. showed that strong
frataxin depletion in yeast cells resulted in complete loss of
mtDNA after 15 generations and that reduced frataxin levels
resulted in only partial loss of mtDNA after 22 generations
[91]. These results indicate that mtDNA loss is dependent
on the frataxin levels in the cell. Recently, it was shown
that in Δyfh1 yeast cells, mtDNA loss is oxygen exposition-
dependent, with complete retention in anaerobic conditions
[51]. Mitochondrial DNA lesions and significant loss in the
heart, cerebellum, and dorsal root ganglia have been observed
in FRDA patients [92, 96–98].
Decades ago, two reports showed evidence of nuclear
DNA damage in skin fibroblasts and blood lymphocytes
of FRDA patients in response to ionizing radiation and
mutagens, respectively [99, 100]. These studies suggested
that in these patients, an increased susceptibility to DNA
damage and/or defective DNA repair pathways were present.
In agreement with this hypothesis, the transcriptome pro-
filing of total blood from 28 children with FRDA revealed
the molecular signature of cell response to DNA damage
[92]. Using quantitative PCR, the same authors showed
increased number of mitochondrial and nuclear DNA lesions
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in blood cells from FRDA patients compared to controls.
A link between frataxin expression, DNA-repair, and tumor
initiation was observed in murine liver [89]. In addition,
this work showed that overexpression of human frataxin in
hamster fibroblasts was associated with a decrease in the
nuclear mutation frequency.
Detailed studies on nuclear DNA damage and repair
pathways have been performed in yeast. Analysis of diploid
frataxin-deficient yeast cells showed evidence of chromo-
somal instability with higher levels of illegitimate mat-
ing, higher rate of spontaneous mutation, and increased
sensitivity to the DNA-alkylating methyl methanesulfonate
and to the replication inhibitor hydroxyurea than controls
[90]. Furthermore, deletion of the glutathione peroxidase
encoding gene GPX1 in frataxin-deficient cells resulted in a
marked increase in the nuclear mutation rate. These results
led the authors to suggest that the increased spontaneous
nuclear damage in Δyfh1 cells was caused by H
2
O
2
generated
in the mitochondria [90]. Consistent with this hypothesis,
the analysis of the exposure of anaerobically grown Δyfh1
cells to oxygen showed that frataxin-deficiency in yeast cells
leads to increased nuclear DNA damage [51]. The effect of
oxygen was very rapid, 15min after Δyfh1 cell exposition to
oxygen, antioxidant levels, were decreased and DNA strand
breaks were visible. At 30min, cell cycle was arrested at
G1/S, and mutation frequency was increased in Δyfh1 cells.
Two hours later, the cells adapted to oxygen since the cell
cycle was reinitiated but were in a chronic oxidative stress
state with a high spontaneous mutation rate. The nuclear
DNA lesions detected in Δyfh1 cells were primarily caused
by oxidized bases and single-strand breaks, and the Apn1
AP-endonuclease of the base excision repair pathway was
essential for the repair these DNA lesions [51]. Altogether,
these observations suggest that DNA damage and repair
could be important features in FRDA disease progression.
6. Antioxidant Therapy
Different strategies for the discovery of effective treatments
for FRDA disease are currently being developed or tested
in clinical trials (see http://www.curefa.org/pipeline.html).
Several groups have done significant advances in FXN gene
replacement or frataxin replacement therapies [101, 102].
Other strategies target the expression of the GAA-expanded
gene (e.g., the HDAC inhibitor RG2833 is in Phase I clin-
ical trial) or the stabilization of the frataxin protein (e.g.,
erythropoietin is in Phase II clinical trial). In addition,
molecules targeting physiological functions that are defective
in patient cells, such as increase in mitochondrial functions
and iron-sulfur cluster synthesis or decrease in oxidative
stress and iron toxicity, are being developed or in clinical
trials. The conclusion of a recent review of the results of all
randomized controlled clinical trials with minimal duration
of 12 months was that none of the pharmacological drugs
tested, including idebenone, had a significant beneficial effect
on the neurological symptoms in FRDA patients [103]. Nev-
ertheless, several ongoing clinical trials are testing promising
antioxidant molecules.The 𝛼-tocopheryl quinone EPI-A0001
is a potent antioxidant molecule that has been tested in
a double-blind, randomized, placebocontrolled trial of two
doses in 31 adults with FRDA for a short period (four
weeks) [104]. Glucose tolerance was tested, and no statistical
difference was observed in the Disposition Index, which is a
measure of diabetic tendency. However, after four weeks of
treatment a dose-dependent improvement in the Friedreich
Ataxia Rating Scale score was observed indicating neurologic
function improvement in the patients. The EPI-743 is a new
drug based on vitamin E that modifies disease progression in
patients suffering from inherited mitochondrial respiratory
chain disorders [105]. A Phase II clinical trial is currently
recruiting FRDA patients. OX1 (indole-3-propionic acid) is a
naturally occurring drug compound that prevents oxidative
stress by a combination of hydroxyl radical scavenging activ-
ity and metal chelation. This molecule is now in preclinical
studies for toxicological safety.
7. Conclusion
In the last decade, major achievements have been obtained
concerning the primary function of frataxin, and it is almost
completely accepted that it is in iron-sulfur cluster synthesis.
Also, the mechanisms that regulate FXN expression with
expanded GAA repeats are well known. However, despite
a strong international effort there is no proven therapy for
FRDA that stops disease progression. One of the reasons
could be that our knowledge of the physiology of frataxin-
deficient cells, and in particular the neurons affected by the
disease, is still reduced. A large number of studies show
that frataxin-deficient cells present numerous pleiotropic
secondary phenotypes, which arise from iron-sulfur clusters
deficit, such as mitochondrial dysfunction, perturbed iron
homeostasis, DNA damage and mutagenesis, and oxidative
stress. However, other areas of research that are relevant
for FRDA pathology and fundamental for the survival and
functioning of neurons are still poorly studied; examples are
mitochondria transport and dynamics, calcium homeostasis,
nitric oxide signaling, and inflammation. A clearer picture
of the effects of frataxin deficiency in neurons and other cell
types that might participate in the degeneration process in
FRDA disease is necessary.
The major problem until recently was the lack of good
in vitro cellular and murine models. The mouse model
that best recapitulates the disease features is the humanized
mouse model (YAC transgenic mice containing the human
FXN gene with 190 GAA repeats) [63]. However, in these
mice the first phenotypes appear after 6 to 12 months of
age, and there is a possibility of GAA trinucleotide repeat
instability. New technologies that can allow the development
of new and relevant models for FRDA disease research
from stem cells have been developed. It is now possible to
obtain individual types of neurons by patterning and differ-
entiation of embryonic stem cells and induced pluripotent
cells (iPS) or also by direct reprogramming of fibroblast or
other cell types. A protocol for differentiation of peripheral
nerve system neurons from human embryonic stem cells
has been published [106]. The first reports of differentiation
of neurons and cardiomyocytes from iPS cells from FRDA
patients are encouraging, although the GAA trinucleotide
Oxidative Medicine and Cellular Longevity 7
repeats are unstable [107, 108]. Liu et al. differentiated sensory
neurons and cardiomyocytes from iPS cells obtained from
FRDA patients [107], andHick et al. describedmitochondrial
deficits in the differentiated cells [109]. In the next years, the
development of these new cell models will greatly contribute
to our knowledge of the neurodegeneration process in FRDA
disease.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
Research on frataxin at the Gomes Laboratory was financed
by the National Ataxia Foundation (USA) and by the
ITQB Strategic Grant PEst-OE/EQB/LA0004/2011 (to ITQB-
Laborato´rio Associado, Oeiras).
References
[1] N. Friedreich, “U¨ber degenerative Atrophie der spinalen Hin-
terstra¨nge,” Virchows Archiv fur Pathologische Anatomie und
Physiologie und fu¨r klinische Medizin, vol. 27, pp. 1–26, 1863.
[2] N. Friedreich, “U¨ber degenerative Atrophie der spinalen Hin-
terstra¨nge,” Virchows Archiv fur Pathologische Anatomie und
Physiologie und fu¨r klinische Medizin, vol. 26, pp. 391–419, 1863.
[3] N. Friedreich, “U¨ber degenerative Atrophie der spinalen Hin-
terstra¨nge,” Virchows Archiv fur Pathologische Anatomie und
Physiologie und fu¨r klinische Medizin, vol. 26, pp. 433–459, 1863.
[4] R. Santos, S. Lefevre, D. Sliwa, A. Seguin, J. Camadro, and
E. Lesuisse, “Friedreich ataxia: molecular mechanisms, redox
considerations, and therapeutic opportunities,” Antioxidants
and Redox Signaling, vol. 13, no. 5, pp. 651–690, 2010.
[5] A. E. Harding, “Friedreich’s ataxia: a clinical and genetic study
of 90 families with an analysis of early diagnostic criteria and
intrafamilial clustering of clinical features,” Brain, vol. 104, no.
3, pp. 589–620, 1981.
[6] A. Du¨rr, M. Cossee, Y. Agid et al., “Clinical and genetic abnor-
malities in patients with Friedreich’s ataxia,” The New England
Journal of Medicine, vol. 335, no. 16, pp. 1169–1175, 1996.
[7] M. Pandolfo, “Friedreich ataxia: the clinical picture,” Journal of
Neurology, vol. 256, supplement 1, pp. 3–8, 2009.
[8] J. T. Hughes, B. Brownell, and R. L. Hewer, “The peripheral sen-
sory pathway in Friedreich’s ataxia: an examination by light and
electronmicroscopy of the posterior nerve roots, posterior root
ganglia, and peripheral sensory nerves in cases of Friedreich’s
ataxia,” Brain, vol. 91, no. 4, pp. 803–818, 1968.
[9] A. H. Koeppen, J. A. Morral, A. N. Davis et al., “The dorsal root
ganglion in Friedreich’s ataxia,” Acta Neuropathologica, vol. 118,
no. 6, pp. 763–776, 2009.
[10] V. Campuzano, L. Montermini, M. D. Molto` et al., “Friedreich’s
ataxia: autosomal recessive disease caused by an intronic GAA
triplet repeat expansion,” Science, vol. 271, no. 5254, pp. 1423–
1427, 1996.
[11] C. Gellera, B. Castellotti, C. Mariotti et al., “Frataxin gene point
mutations in Italian Friedreich ataxia patients,” Neurogenetics,
vol. 8, no. 4, pp. 289–299, 2007.
[12] S. I. Bidichandani, T.Ashizawa, andP. I. Patel, “TheGAA triplet-
repeat expansion in Friedreich ataxia interferes with transcrip-
tion and may be associated with an unusual DNA structure,”
American Journal of Human Genetics, vol. 62, no. 1, pp. 111–121,
1998.
[13] E. Grabczyk, M. Mancuso, and M. C. Sammarco, “A persistent
RNA⋅DNA hybrid formed by transcription of the Friedreich
ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro,”
Nucleic Acids Research, vol. 35, no. 16, pp. 5351–5359, 2007.
[14] S. Al-Mahdawi, R. M. Pinto, O. Ismail et al., “The Friedreich
ataxia GAA repeat expansion mutation induces comparable
epigenetic changes in human and transgenic mouse brain and
heart tissues,”HumanMolecular Genetics, vol. 17, no. 5, pp. 735–
746, 2008.
[15] D. Herman, K. Jenssen, R. Burnett, E. Soragni, S. L. Perlman,
and J. M. Gottesfeld, “Histone deacetylase inhibitors reverse
gene silencing in Friedreich’s ataxia,” Nature Chemical Biology,
vol. 2, no. 10, pp. 551–558, 2006.
[16] P. K. Chan, R. Torres, C. Yandim et al., “Heterochromatinization
induced by GAA-repeat hyperexpansion in Friedreich’s ataxia
can be reduced upon HDAC inhibition by vitamin B3,”Human
Molecular Genetics, 2013.
[17] R. A. Vaubel and G. Isaya, “Iron-sulfur cluster synthesis, iron
homeostasis and oxidative stress in Friedreich ataxia,”Molecular
and Cellular Neuroscience, vol. 55, pp. 50–61.
[18] T. L. Stemmler, E. Lesuisse, D. Pain, and A. Dancis, “Frataxin
and mitochondrial FeS cluster biogenesis,” The Journal of
Biological Chemistry, vol. 285, no. 35, pp. 26737–26743, 2010.
[19] T. A. Rouault, “Biogenesis of iron-sulfur clusters in mammalian
cells: new insights and relevance to human disease,” DMM
Disease Models and Mechanisms, vol. 5, no. 2, pp. 155–164, 2012.
[20] R. Lill, B. Hoffmann, S. Molik et al., “The role of mitochondria
in cellular iron-sulfur protein biogenesis and iron metabolism,”
Biochimica et Biophysica Acta, vol. 1823, no. 9, pp. 1491–1508,
2012.
[21] I. De Biase, A. Rasmussen, D. Endres et al., “Progressive GAA
expansions in dorsal root ganglia of Friedreich’s ataxia patients,”
Annals of Neurology, vol. 61, no. 1, pp. 55–60, 2007.
[22] I. De Biase, A. Rasmussen, A. Monticelli et al., “Somatic
instability of the expanded GAA triplet-repeat sequence in
Friedreich ataxia progresses throughout life,”Genomics, vol. 90,
no. 1, pp. 1–5, 2007.
[23] J. S. Armstrong, O. Khdour, and S. M. Hecht, “Does oxidative
stress contribute to the pathology of Friedreich’s ataxia? A
radical question,” The FASEB Journal, vol. 24, no. 7, pp. 2152–
2163, 2010.
[24] A. Bayot, R. Santos, J. Camadro, and P. Rustin, “Friedreich’s
ataxia: the vicious circle hypothesis revisited,” BMC Medicine,
vol. 9, article 112, 2011.
[25] S. Cho, M. G. Lee, J. K. Yang, J. Y. Lee, H. K. Song, and S. W.
Suh, “Crystal structure of Escherichia coli CyaY protein reveals
a previously unidentified fold for the evolutionarily conserved
frataxin family,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 97, no. 16, pp. 8932–8937,
2000.
[26] S. Dhe-Paganon, R. Shigeta, Y. Chi, M. Ristow, and S. E.
Shoelson, “Crystal structure of human frataxin,”The Journal of
Biological Chemistry, vol. 275, no. 40, pp. 30753–30756, 2000.
[27] Y. He, S. L. Alam, S. V. Proteasa et al., “Yeast frataxin solution
structure, iron binding, and ferrochelatase interaction,” Bio-
chemistry, vol. 43, no. 51, pp. 16254–16262, 2004.
8 Oxidative Medicine and Cellular Longevity
[28] G. Musco, T. de Tommasi, G. Stier et al., “Assignment of the
1H, 15N, and 13C resonances of the C-terminal domain of
frataxin, the protein responsible for Friedreich ataxia,” Journal
of Biomolecular NMR, vol. 15, no. 1, pp. 87–88, 1999.
[29] M. Nair, S. Adinolfi, C. Pastore, G. Kelly, P. Temussi, and A.
Pastore, “Solution structure of the bacterial frataxin ortholog,
CyaY: mapping the iron binding sites,” Structure, vol. 12, no. 11,
pp. 2037–2048, 2004.
[30] F. Prischi, P. V. Konarev, C. Iannuzzi et al., “Structural bases for
the interaction of frataxin with the central components of iron-
sulphur cluster assembly,” Nature Communications, vol. 1, no. 7,
article 95, 2010.
[31] H. Li, O. Gakh, D. Y. Smith IV, and G. Isaya, “Oligomeric yeast
frataxin drives assembly of core machinery for mitochondrial
iron-sulfur cluster synthesis,” The Journal of Biological Chem-
istry, vol. 284, no. 33, pp. 21971–21980, 2009.
[32] C. Iannuzzi, S. Adinolfi, B. D. Howes et al., “The role of cyay in
iron sulfur cluster assembly on the E. coli iscu scaffold protein,”
PLoS ONE, vol. 6, no. 7, Article ID e21992, 2011.
[33] F. Foury, A. Pastore, and M. Trincal, “Acidic residues of yeast
frataxin have an essential role in Fe-S cluster assembly,” EMBO
Reports, vol. 8, no. 2, pp. 194–199, 2007.
[34] T. Wang and E. A. Craig, “Binding of yeast frataxin to the
scaffold for Fe-S cluster biogenesis, Isu,”The Journal of Biological
Chemistry, vol. 283, no. 18, pp. 12674–12679, 2008.
[35] A. R. Correia, T. Wang, E. A. Craig, and C. M. Gomes, “Iron-
binding activity in yeast frataxin entails a trade off with stability
in the 𝛼1/𝛽1 acidic ridge region,” Biochemical Journal, vol. 426,
no. 2, pp. 197–203, 2010.
[36] P. Cavadini, J. Adamec, F. Taroni, O. Gakh, and G. Isaya, “Two-
step processing of human frataxin by mitochondrial processing
peptidase: precursor and intermediate forms are cleaved at
different rates,”The Journal of Biological Chemistry, vol. 275, no.
52, pp. 41469–41475, 2000.
[37] S. Schmucker, M. Argentini, N. Carelle-Calmels, A. Martelli,
and H. Puccio, “The in vivomitochondrial two-step maturation
of human frataxin,” Human Molecular Genetics, vol. 17, no. 22,
pp. 3521–3531, 2008.
[38] I. Condo`, N. Ventura, F.Malisan, A. Rufini, B. Tomassini, and R.
Testi, “In vivomaturation of human frataxin,”HumanMolecular
Genetics, vol. 16, no. 13, pp. 1534–1540, 2007.
[39] O. Gakh, T. Bedekovics, S. F. Duncan, D. Y. Smith IV, D. S.
Berkholz, and G. Isaya, “Normal and Friedreich ataxia cells
express different isoforms of frataxin with complementary
roles in iron-sulfur cluster assembly,” The Journal of Biological
Chemistry, vol. 285, no. 49, pp. 38486–38501, 2010.
[40] A. Seguin, A. Bayot, A. Dancis et al., “Overexpression of the
yeast frataxin homolog (Yfh1): contrasting effects on iron-sulfur
cluster assembly, heme synthesis and resistance to oxidative
stress,”Mitochondrion, vol. 9, no. 2, pp. 130–138, 2009.
[41] O. Gakh, D. Y. Smith IV, and G. Isaya, “Assembly of the iron-
binding protein frataxin in Saccharomyces cerevisiae responds to
dynamic changes in mitochondrial iron influx and stress level,”
The Journal of Biological Chemistry, vol. 283, no. 46, pp. 31500–
31510, 2008.
[42] A. R. Correia, S. Y. Ow, P. C. Wright, and C. M. Gomes,
“The conserved Trp155 in human frataxin as a hotspot for
oxidative stress related chemical modifications,” Biochemical
and Biophysical Research Communications, vol. 390, no. 3, pp.
1007–1011, 2009.
[43] M. Cossee, A. Durr, M. Schmitt et al., “Friedreich’s ataxia: point
mutations and clinical presentation of compound heterozy-
gotes,” Annals of Neurology, vol. 45, no. 2, pp. 200–206, 1999.
[44] A. R. Correia, S. Adinolfi, A. Pastore, and C. M. Gomes, “Con-
formational stability of human frataxin and effect of Friedreich’s
ataxia-related mutations on protein folding,” Biochemical Jour-
nal, vol. 398, no. 3, pp. 605–611, 2006.
[45] A. R. Correia, C. Pastore, S. Adinolfi, A. Pastore, and C.
M. Gomes, “Dynamics, stability and iron-binding activity of
frataxin clinical mutants,” FEBS Journal, vol. 275, no. 14, pp.
3680–3690, 2008.
[46] N. Calmels, S. Schmucker, M. Wattenhofer-Donze´ et al., “The
first cellular models based on frataxin missense mutations that
reproduce spontaneously the defects associated with Friedreich
ataxia,” PLoS ONE, vol. 4, no. 7, Article ID e6379, 2009.
[47] H. Li, O. Gakh, D. Y. T. Smith, W. K. Ranatunga, and G. Isaya,
“Missense mutations linked to Friedreich ataxia have different
but synergistic effects on mitochondrial frataxin isoforms,”The
Journal of Biological Chemistry, vol. 288, no. 6, pp. 4116–4127,
2013.
[48] A. Bayot, S. Reichman, S. Lebon et al., “Cis-silencing of
PIP5K1B evidenced in Friedreich’s ataxia patient cells results in
cytoskeleton anomalies,” Human Molecular Genetics, 2013.
[49] S. S. Leal, H. M. Botelho, and C. M. Gomes, “Metal ions
as modulators of protein conformation and misfolding in
neurodegeneration,” Coordination Chemistry Reviews, vol. 256,
no. 19-20, pp. 2253–2270, 2012.
[50] C.M.Gomes, “Proteinmisfolding in disease and smallmolecule
therapies,”Current Topics inMedicinal Chemistry, vol. 12, no. 22,
pp. 2460–2469, 2012.
[51] S. Lefevre, C. Brossas, F. Auche`re, N. Boggetto, J. M. Camadro,
and R. Santos, “Apn1 AP-endonuclease is essential for the repair
of oxidatively damaged DNA bases in yeast frataxin-deficient
cells,”HumanMolecular Genetics, vol. 21, no. 18, pp. 4060–4072,
2012.
[52] Y. Shan, R. A. Schoenfeld, G. Hayashi et al., “Frataxin defi-
ciency leads to defects in expression of antioxidants and Nrf2
expression in dorsal root ganglia of the Friedreich’s ataxia YG8R
mouse model,” Antioxidants & Redox Signaling, 2013.
[53] E. Napoli, F. Taroni, and G. A. Cortopassi, “Frataxin, iron-
sulfur clusters, heme, ROS, and aging,” Antioxidants and Redox
Signaling, vol. 8, no. 3-4, pp. 506–516, 2006.
[54] V. Irazusta, E. Cabiscol, G. Reverter-Branchat, J. Ros, and J.
Tamarit, “Manganese is the link between frataxin and iron-
sulfur deficiency in the yeast model of Friedreich ataxia,” The
Journal of Biological Chemistry, vol. 281, no. 18, pp. 12227–12232,
2006.
[55] M. M. Santos, K. Ohshima, and M. Pandolfo, “Frataxin defi-
ciency enhances apoptosis in cells differentiating into neuroec-
toderm,” Human Molecular Genetics, vol. 10, no. 18, pp. 1935–
1944, 2001.
[56] P. R. Anderson, K. Kirby, W. C. Orr, A. J. Hilliker, and J. P.
Phillips, “Hydrogen peroxide scavenging rescues frataxin defi-
ciency in aDrosophilamodel of Friedreich’s ataxia,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 105, no. 2, pp. 611–616, 2008.
[57] V. Paupe, E. P. Dassa, S. Goncalves et al., “Impaired nuclear
Nrf2 translocation undermines the oxidative stress response in
Friedreich ataxia,” PLoS ONE, vol. 4, no. 1, Article ID e4253,
2009.
Oxidative Medicine and Cellular Longevity 9
[58] S. Lefevre, D. Sliwa, F. Auchre et al., “The yeast metacaspase is
implicated in oxidative stress response in frataxin-deficient
cells,” FEBS Letters, vol. 586, no. 2, pp. 143–148, 2012.
[59] R. Santos, N. Buisson, S. A. B. Knight, A. Dancis, J. Camadro,
and E. Lesuisse, “Candida albicans lacking the frataxin homo-
logue: a relevant yeast model for studying the role of frataxin,”
Molecular Microbiology, vol. 54, no. 2, pp. 507–519, 2004.
[60] R. P. Va´zquez-Manrique, P. Gonza´lez-Cabo, S. Ros, H. Aziz,
H. A. Baylis, and F. Palau, “Reduction of Caenorhabditis
elegans frataxin increases sensitivity to oxidative stress, reduces
lifespan, and causes lethality in a mitochondrial complex II
mutant,”The FASEB Journal, vol. 20, no. 1, pp. 172–174, 2006.
[61] J. V. Llorens, J. A. Navarro, M. J. Mart´ınez-Sebast´ıan et al.,
“Causative role of oxidative stress in a Drosophila model of
Friedreich ataxia,” The FASEB Journal, vol. 21, no. 2, pp. 333–
344, 2007.
[62] A. P. Runko, A. J. Griswold, and K. Min, “Overexpression of
frataxin in the mitochondria increases resistance to oxidative
stress and extends lifespan inDrosophila,” FEBS Letters, vol. 582,
no. 5, pp. 715–719, 2008.
[63] S. Al-Mahdawi, R. M. Pinto, D. Varshney et al., “GAA repeat
expansion mutation mouse models of Friedreich ataxia exhibit
oxidative stress leading to progressive neuronal and cardiac
pathology,” Genomics, vol. 88, no. 5, pp. 580–590, 2006.
[64] G. Tozzi,M.Nuccetelli, M. Lo Bello et al., “Antioxidant enzymes
in blood of patients with Friedreich’s ataxia,” Archives of Disease
in Childhood, vol. 86, no. 5, pp. 376–379, 2002.
[65] S. Jiralerspong, B. Ge, T. J. Hudson, and M. Pandolfo, “Man-
ganese superoxide dismutase induction by iron is impaired in
Friedreich ataxia cells,” FEBS Letters, vol. 509, no. 1, pp. 101–105,
2001.
[66] K. Chantrel-Groussard, V. Geromel, H. Puccio et al., “Disabled
early recruitment of antioxidant defenses in Friedreich’s ataxia,”
Human Molecular Genetics, vol. 10, no. 19, pp. 2061–2067, 2001.
[67] G. Tan, L. Chen, B. Lonnerdal, C. Gellera, F. A. Taroni, and
G. A. Cortopassi, “Frataxin expression rescues mitochondrial
dysfunctions in FRDA cells,”HumanMolecular Genetics, vol. 10,
no. 19, pp. 2099–2107, 2001.
[68] A. Wong, J. Yang, P. Cavadini et al., “The Friedreich’s ataxia
mutation confers cellular sensitivity to oxidant stress which
is rescued by chelators of iron and calcium and inhibitors of
apoptosis,” Human Molecular Genetics, vol. 8, no. 3, pp. 425–
430, 1999.
[69] V. Calabrese, R. Lodi, C. Tonon et al., “Oxidative stress,
mitochondrial dysfunction and cellular stress response in
Friedreich’s ataxia,” Journal of the Neurological Sciences, vol. 233,
no. 1-2, pp. 145–162, 2005.
[70] A. Bulteau, A. Dancis, M. Gareil, J. Montagne, J. Camadro,
and E. Lesuisse, “Oxidative stress and protease dysfunction in
the yeast model of Friedreich ataxia,” Free Radical Biology and
Medicine, vol. 42, no. 10, pp. 1561–1570, 2007.
[71] M. M. Gallogly and J. J. Mieyal, “Mechanisms of reversible
protein glutathionylation in redox signaling and oxidative
stress,” Current Opinion in Pharmacology, vol. 7, no. 4, pp. 381–
391, 2007.
[72] F. Piemonte, A. Pastore, G. Tozzi et al., “Glutathione in blood of
patients with Friedreich’s ataxia,” European Journal of Clinical
Investigation, vol. 31, no. 11, pp. 1007–1011, 2001.
[73] F. Auche`re, R. Santos, S. Planamente, E. Lesuisse, and J.
Camadro, “Glutathione-dependent redox status of frataxin-
deficient cells in a yeast model of Friedreich’s ataxia,” Human
Molecular Genetics, vol. 17, no. 18, pp. 2790–2802, 2008.
[74] A. Pastore, G. Tozzi, L. M. Gaeta et al., “Actin glutathionylation
increases in fibroblasts of patients with Friedreich’s ataxia: a
potential role in the pathogenesis of the disease,” The Journal
of Biological Chemistry, vol. 278, no. 43, pp. 42588–42595, 2003.
[75] A. L. Bulteau, S. Planamente, L. Jornea et al., “Changes in mito-
chondrial glutathione levels and protein thiol oxidation inΔyfh1
yeast cells and the lymphoblasts of patients with Friedreich’s
ataxia,” Biochimica et Biophysica Acta, vol. 1822, no. 2, pp. 212–
225, 2012.
[76] M. Sparaco, L. M. Gaeta, F. M. Santorelli et al., “Friedreich’s
ataxia: oxidative stress and cytoskeletal abnormalities,” Journal
of the Neurological Sciences, vol. 287, no. 1-2, pp. 111–118, 2009.
[77] T. Nguyen, P. Nioi, and C. B. Pickett, “The Nrf2-antioxidant
response element signaling pathway and its activation by
oxidative stress,” The Journal of Biological Chemistry, vol. 284,
no. 20, pp. 13291–13295, 2009.
[78] V. D’Oria, S. Petrini, L. Travaglini et al., “Frataxin deficiency
leads to reduced expression and impaired translocation of NF-
E2-related factor (Nrf2) in cultured motor neurons,” Interna-
tional Journal ofMolecular Sciences, vol. 10, no. 4, pp. 7853–7865,
2013.
[79] T. Philips and W. Robberecht, “Neuroinflammation in amy-
otrophic lateral sclerosis: role of glial activation inmotor neuron
disease,”The Lancet Neurology, vol. 10, no. 3, pp. 253–263, 2011.
[80] C. Lu, R. Schoenfeld, Y. Shan, H. Tsai, B. Hammock, and G.
Cortopassi, “Frataxin deficiency induces Schwann cell inflam-
mation and death,” Biochimica et Biophysica Acta, vol. 1792, no.
11, pp. 1052–1061, 2009.
[81] J. Newbern and C. Birchmeier, “Nrg1/ErbB signaling networks
in Schwann cell development andmyelination,” Seminars in Cell
and Developmental Biology, vol. 21, no. 9, pp. 922–928, 2010.
[82] K. Nave and B. D. Trapp, “Axon-glial signaling and the glial
support of axon function,” Annual Review of Neuroscience, vol.
31, pp. 535–561, 2008.
[83] J. A. Morral, A. N. Davis, J. Qian, B. B. Gelman, and A. H.
Koeppen, “Pathology and pathogenesis of sensory neuropathy
in Friedreich’s ataxia,” Acta Neuropathologica, vol. 120, no. 1, pp.
97–108, 2010.
[84] M. S. Cooke, M. D. Evans, M. Dizdaroglu, and J. Lunec,
“Oxidative DNA damage: mechanisms, mutation, and disease,”
The FASEB Journal, vol. 17, no. 10, pp. 1195–1214, 2003.
[85] D. Svilar, E. M. Goellner, K. H. Almeida, and R.W. Sobol, “Base
excision repair and lesion-dependent subpathways for repair of
oxidative DNA damage,” Antioxidants and Redox Signaling, vol.
14, no. 12, pp. 2491–2507, 2011.
[86] L. Gros, M. K. Saparbaev, and J. Laval, “Enzymology of the
repair of free radicals-inducedDNAdamage,”Oncogene, vol. 21,
no. 58, pp. 8905–8925, 2002.
[87] J. B. Schulz, T. Dehmer, L. Scho¨ls et al., “Oxidative stress in
patients with Friedreich ataxia,” Neurology, vol. 55, no. 11, pp.
1719–1721, 2000.
[88] N. A. Di Prospero, A. Baker, N. Jeffries, and K. H. Fischbeck,
“Neurological effects of high-dose idebenone in patients with
Friedreich’s ataxia: a randomised, placebo-controlled trial,”The
Lancet Neurology, vol. 6, no. 10, pp. 878–886, 2007.
[89] R. Thierbach, G. Drewes, M. Fusser et al., “The Friedreich’s
ataxia protein frataxin modulates DNA base excision repair in
prokaryotes and mammals,” Biochemical Journal, vol. 432, no. 1,
pp. 165–172, 2010.
[90] G. Karthikeyan, L. K. Lewis, and M. A. Resnick, “The mito-
chondrial protein frataxin prevents nuclear damage,” Human
Molecular Genetics, vol. 11, no. 11, pp. 1351–1362, 2002.
10 Oxidative Medicine and Cellular Longevity
[91] G. Karthikeyan, J. H. Santos,M.A.Graziewicz et al., “Reduction
in frataxin causes progressive accumulation of mitochondrial
damage,” Human Molecular Genetics, vol. 12, no. 24, pp. 3331–
3342, 2003.
[92] A. C. Haugen, N. A. Di Prospero, J. S. Parker et al., “Altered gene
expression and DNA damage in peripheral blood cells from
Friedreich’s ataxia patients: cellular model of pathology,” PLoS
Genetics, vol. 6, no. 1, Article ID e1000812, 2010.
[93] R. B.Wilson andD.M. Roof, “Respiratory deficiency due to loss
of mitochondrial dna in yeast lacking the frataxin homologue,”
Nature Genetics, vol. 16, no. 4, pp. 352–357, 1997.
[94] M. Babcock, D. de Silva, R. Oaks et al., “Regulation of mito-
chondrial iron accumulation by Yfh1p, a putative homolog of
frataxin,” Science, vol. 276, no. 5319, pp. 1709–1712, 1997.
[95] F. Foury and O. Cazzalini, “Deletion of the yeast homologue of
the human gene associated with Friedreich’s ataxia elicits iron
accumulation in mitochondria,” FEBS Letters, vol. 411, no. 2-3,
pp. 373–377, 1997.
[96] J. L. Bradley, J. C. Blake, S. Chamberlain, P. K. Thomas, J.
M. Cooper, and A. H. V. Schapira, “Clinical, biochemical and
molecular genetic correlations in Friedreich’s ataxia,” Human
Molecular Genetics, vol. 9, no. 2, pp. 275–282, 2000.
[97] M. Houshmand, M. S. S. Panahi, S. Nafisi, A. Soltanzadeh, and
F.M. Alkandari, “Identification and sizing of GAA trinucleotide
repeat expansion, investigation for D-loop variations andmito-
chondrial deletions in Iranian patients with Friedreich’s ataxia,”
Mitochondrion, vol. 6, no. 2, pp. 82–88, 2006.
[98] M. M. Heidari, M. Houshmand, S. Hosseinkhani, S. Nafissi, B.
Scheiber-Mojdehkar, and M. Khatami, “A novel mitochondrial
heteroplasmic C13806A point mutation associated with iranian
Friedreich’s ataxia,” Cellular and Molecular Neurobiology, vol.
29, no. 2, pp. 225–233, 2009.
[99] H. J. Evans, V. Vijayalaxmi, B. Pentland, and M. S. Newton,
“Mutagen hypersensitivity in Friedreich’s ataxia,” Annals of
Human Genetics, vol. 47, no. 3, pp. 193–204, 1983.
[100] P. D. Lewis, J. B. Corr, C. F. Arlett, and S. A. Harcourt,
“Increased sensitivity to gamma irradiation of skin fibroblasts
in Friedreich’s ataxia,”The Lancet, vol. 2, no. 8140, pp. 474–475,
1979.
[101] A. Gimenez-Cassina, R.Wade-Martins, S. Gomez-Sebastian, J.-
C. Corona, F. Lim, and J. Diaz-Nido, “Infectious delivery and
long-term persistence of transgene expression in the brain by
a 135-kb iBAC-FXN genomic DNA expression vector,” Gene
Therapy, vol. 18, no. 10, pp. 1015–1019, 2011.
[102] P. M. Vyas, W. J. Tomamichel, P. M. Pride et al., “A TAT-frataxin
fusion protein increases lifespan and cardiac function in a
conditional Friedreich’s ataxiamousemodel,”HumanMolecular
Genetics, vol. 21, no. 6, Article ID ddr554, pp. 1230–1247, 2012.
[103] M. Kearney, R. W. Orrell, M. Fahey, and M. Pandolfo, “Antiox-
idants and other pharmacological treatments for Friedreich
ataxia,” Cochrane Database of Systematic Reviews, no. 4, Article
ID CD007791, 2009.
[104] D. R. Lynch, S. M.Willi, R. B.Wilson et al., “A0001 in Friedreich
ataxia: biochemical characterization and effects in a clinical
trial,”Movement Disorders, vol. 27, no. 8, pp. 1026–1033, 2012.
[105] G. M. Enns, S. L. Kinsman, S. L. Perlman et al., “Initial
experience in the treatment of inherited mitochondrial disease
with EPI-743,”Molecular Genetics and Metabolism, vol. 105, no.
1, pp. 91–102, 2012.
[106] M. Valensi-Kurtz, S. Lefler, M. A. Cohen et al., “Enriched
population of PNS neurons derived from human embryonic
stem cells as a platform for studying peripheral neuropathies,”
PLoS ONE, vol. 5, no. 2, Article ID e9290, 2010.
[107] J. Liu, P. J. Verma, M. V. Evans-Galea et al., “Generation
of induced pluripotent stem cell lines from Friedreich ataxia
patients,” Stem Cell Reviews and Reports, vol. 7, no. 3, pp. 703–
713, 2011.
[108] S. Ku, E. Soragni, E. Campau et al., “Friedreich’s ataxia induced
pluripotent stem cells model intergenerational GAATTC triplet
repeat instability,” Cell Stem Cell, vol. 7, no. 5, pp. 631–637, 2010.
[109] A. Hick, M. Wattenhofer-Donze´, S. Chintawar et al., “Neurons
and cardiomyocytes derived from induced pluripotent stem
cells as amodel formitochondrial defects in Friedreich’s ataxia,”
Disease Models & Mechanisms, vol. 6, no. 3, pp. 608–621, 2013.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Mediators
inflaMMation
of
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Computational and 
Mathematical Methods 
in Medicine
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
